Unexpected Efficacy of a Novel Sodium Channel Modulator in Dravet Syndrome
Open Access
- 10 May 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 7 (1), 1682
- https://doi.org/10.1038/s41598-017-01851-9
Abstract
Dravet syndrome, an epileptic encephalopathy affecting children, largely results from heterozygous loss-of-function mutations in the brain voltage-gated sodium channel gene SCN1A. Heterozygous Scn1a knockout (Scn1a +/−) mice recapitulate the severe epilepsy phenotype of Dravet syndrome and are an accepted animal model. Because clinical observations suggest conventional sodium channel blocking antiepileptic drugs may worsen the disease, we predicted the phenotype of Scn1a +/− mice would be exacerbated by GS967, a potent, unconventional sodium channel blocker. Unexpectedly, GS967 significantly improved survival of Scn1a +/− mice and suppressed spontaneous seizures. By contrast, lamotrigine exacerbated the seizure phenotype. Electrophysiological recordings of acutely dissociated neurons revealed that chronic GS967-treatment had no impact on evoked action potential firing frequency of interneurons, but did suppress aberrant spontaneous firing of pyramidal neurons and was associated with significantly lower sodium current density. Lamotrigine had no effects on neuronal excitability of either neuron subtype. Additionally, chronically GS967-treated Scn1a +/− mice exhibited normalized pyramidal neuron sodium current density and reduced hippocampal NaV1.6 protein levels, whereas lamotrigine treatment had no effect on either pyramidal neuron sodium current or hippocampal NaV1.6 levels. Our findings demonstrate unexpected efficacy of a novel sodium channel blocker in Dravet syndrome and suggest a potential mechanism involving a secondary change in NaV1.6.This publication has 38 references indexed in Scilit:
- Dravet syndrome—From epileptic encephalopathy to channelopathyEpilepsia, 2014
- Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosisHuman Molecular Genetics, 2014
- De novo mutations in epileptic encephalopathiesNature, 2013
- The SCN1A gene variants and epileptic encephalopathiesJournal of Human Genetics, 2013
- Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1Nature Genetics, 2013
- Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsyOrphanet Journal of Rare Diseases, 2013
- Dravet syndrome (severe myoclonic epilepsy in infancy)Handbook of Clinical Neurology, 2013
- Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndromeBrain, 2012
- Severe myoclonic epilepsy in infancy (Dravet syndrome) 30 years laterEpilepsia, 2011
- Genome-Wide Copy Number Variation in Epilepsy: Novel Susceptibility Loci in Idiopathic Generalized and Focal EpilepsiesPLoS Genetics, 2010